Company intelligence / Profile preview

Amporin Pharmaceuticals

Basel, Basel-Stadt, Switzerland

Ownership: Private
Development stage: Preclinical

Overview

The company has demonstrated Proof of Concept with acute oral disease reversal in vivo. A single oral dose of their prototype drug candidate fully restored cognitive and motor function in two established animal models of Alzheimer's and Parkinson's disease, with no adverse effects in normal healthy animals[5].

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

Amportacs

Preclinical

Beyond the preview

Go deeper on Amporin Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amporin Pharmaceuticals.

Explore the full profile